iTOF is the first mobile device-managed quantitative monitor of Neuromuscular Blocking Agents (NMBAs) that provides accuracy and ease of use in surgical anesthesia and ICU mechanical ventilation.
iTOF consists of a standard alkaline 9v battery, a Bluetooth-connected stimulator device, and its iTOF App that connects to and manages multiple stimulators. This combination allows precise, automated quantitative monitoring of the level of neuromuscular blocking.
We are transforming smartphones and tablets into medical devices with high accuracy, reliability, and availability—while allowing easy patient-specific calibration and automation and improving healthcare worker safety. HIPAA-compliant AI-assisted data analysis and automated reporting help physicians improve patient care.
The patent-pending iTOF comprises a nerve stimulation device and a twitch-sensing accelerometer wirelessly connected to a smartphone or tablet. Stimulation data transmit to one or more connected devices that precisely quantize the stimulation results while providing complete control of settings, calibrations, and alerts to manage the anesthetized patient.
Multi-user accessibility and ease of use help eliminate Critical Respiratory Events (CRE) due to residual NMBAs in the post-anesthesia care unit (PACU) and unmonitored patients in the ICU.
Our HIPAA-compliant software platform aggregates all data in a secure, managed cloud service. The iTOF backend services include machine learning algorithms that analyze patient data to improve procedural accuracy and optimize device utilization.
"The monitor operates through an application with a smartphone connected by a Bluetooth system, which works systematically, without problems in the different mobile phones and their operating systems. The device is easy to apply and clinical use; it shows reliable quantitative values and is easy to interpret. We find it versatile and safe, in addition to having a solid accelerometer resistant to regular use".
Dra. Maria Mercedes Aguirre
Director - Anesthesiology and Perioperative Medical Dept.
Hospital Clinico Universidad de Chile
"Has been a significant contribution. In our hospital, monitors are scarce. To implement new critical units, simply non-existent or unattainable by cost, to date iTOF are in uninterrupted use in critical patient units".
Dr. Sebastián Monsalves
Anesthesiologist of Clinica Alemana.
President of the Airway Committee, Chilean Society of Anesthesiology (SACH).
"I start using the iTOF to monitor neuromuscular blockade in hospitalized patients in our intensive care units amid the COVID-19 pandemic." According to national and international guidelines today, neuromuscular blockade in these patients strongly suggests quantitative monitoring. The remote monitoring of patients, offering less exposure of health personnel and personal protection elements, and our nursing staff has widely accepted it."
Dr. David Barra Ortiz
Anesthesiology at Hospital Clinico San Borja Arriarán, Santiago Chile.
Member of the Chilean Society of Anesthesiology (SACH).
"The iTOF allows doctors to improve daily clinical practice using a more precise dose of neuromuscular blocker, saving the amount used in the patient's anesthesia induction. It also helps to reduce the amount of neuromuscular reversers because, still under the effect of the blocker, they can choose whether to use or avoid highly expensive reversers. In summary, an excellent device for the impact on the quality care of our patients by rationally using neuromuscular blockers".
Dra. Marinka Gladic, Dr. Ian Mir, and Dr. Roberto Vergara
Hospital Carlos Cisternas de Calama
iTOF is improving patient care in Operating Rooms and ICUs in Chile.
Nerbio Medical Software Platforms, Inc.
1900 Camden Ave , San Jose, CA 95124 USA
Contact +1 (408) 809 3296
Nerbio® and iTOF® are registered trademarks of Nerbio Medical Software Platforms, Inc. Copyright © 2023 Nerbio - All Rights Reserved.